Mind & Body · 12 min read

Menopause Weight Loss: What Works, From Diet to GLP-1s

A woman in her fifties walking along a sunny lakeside boardwalk lined with trees.
Federal guidelines start at 150 minutes a week of moderate activity. For keeping weight off, the NIDDK says some people need more than twice that.
The short answer

Menopause weight loss doesn't need to be dramatic: with overweight or obesity, the NIDDK says losing 5% to 10% may lower blood sugar, blood pressure and triglycerides, and The Menopause Society says weight loss may ease hot flashes for some women. Diet and activity come first. Prescription GLP-1 drugs add more for some; compounded versions carry FDA warnings.

If you've read our article on menopause weight gain, you know the scale often isn't the best measure of what changed. This article is the other half of that conversation: if you do want to lose weight in midlife, what does the evidence say actually works, how much is worth aiming for, and where are the traps?

It covers the targets that matter for health, what weight loss can do for hot flashes, what a very large diet trial in postmenopausal women found, how much exercise the federal guidance suggests, how the newer GLP-1 medicines fit, the FDA's warnings about compounded and online versions, and what the evidence says about berberine and peptides.

How much weight do you need to lose to make a difference?

Less than most of us assume. For people with overweight or obesity, the NIDDK says losing 5% to 10% of your starting weight may help improve your health by lowering blood sugar, blood pressure and triglycerides. It adds that losing weight can also improve other problems related to overweight and obesity, such as joint pain and sleep apnea.

5–10%
"Weight loss of 5% to 10% of your starting body weight may help improve your health by lowering blood sugar, blood pressure, and triglyceride levels." For a 180-pound woman, that's 9 to 18 pounds. Source: NIDDK, Prescription Medications to Treat Overweight & Obesity. The pound figures are our arithmetic.

In my reading, that range is worth holding onto, because so much menopause weight-loss marketing promises far more. A goal you can reach and keep is worth more than a bigger number you can't.

Can losing weight help hot flashes?

For some women, it may. The Menopause Society's 2023 nonhormone position statement lists weight loss among its recommended treatments for hot flashes, at Levels II–III, meaning the evidence is limited and partly expert opinion. It notes that women with obesity are more likely to report more frequent and severe hot flashes.

It says randomized trials have found that weight loss from behavioral programs is associated with fewer hot flashes, and that the effect may be greater earlier in the transition, in perimenopause and early postmenopause, than later. It's also candid about the limits: the studies are small pilots, nonrandomized trials or analyses of trials designed for something else, and larger trials are needed. Its conclusion: "weight loss may be used to improve VMS for some women."

Our hot flashes guide covers the treatments with stronger evidence, and our weight gain article looks at what's known about weight and night sweats.

Which diet works best for menopause weight loss?

A very large trial in postmenopausal women wasn't even trying to produce weight loss, which makes its result interesting. The Women's Health Initiative Dietary Modification Trial randomized 48,835 postmenopausal women in the US to a program that cut fat and added vegetables, fruit and grains, or to a control group. It set no weight-loss or calorie goals.

Women in the eating program lost an average of 2.2 kg (about 5 pounds) in the first year and stayed lighter than the control group for an average of 7.5 years, although the gap narrowed from 1.9 kg at one year to 0.4 kg by the end. Weight loss was greatest among women in either group who reduced the share of their calories from fat, with a similar but smaller trend for eating more vegetables and fruit.

In my reading, two lessons come out of it. A sustainable eating pattern, without calorie counting, moved weight a little and kept it from creeping up for years. And the effect was modest, which is a useful reality check against any diet sold as the menopause answer. If you prefer a less restrictive pattern, our Mediterranean diet article covers that evidence.

Diet alone and hot flashes. The Menopause Society reviewed dietary changes separately from weight loss and found limited evidence from clinical trials that changing what you eat, on its own, improves hot flashes. It still calls a healthy diet "important for health promotion and chronic disease prevention."

How much exercise does it take to lose weight in midlife?

Possibly more than the minimum. The NIDDK points to the federal physical activity guidelines, which recommend at least 150 minutes a week of moderate-intensity aerobic activity and at least 2 days a week of muscle-strengthening activities. It adds that you may need more than 300 minutes of moderate-intensity activity a week to reach or maintain your weight-loss goal.

Muscle-strengthening is part of the federal recommendation, not an extra. Muscle in midlife is covered in our articles on menopause muscle loss and creatine. If exercise is new to you, our guide to exercise and sleep in menopause covers how activity and sleep affect each other.

Do GLP-1 drugs like semaglutide and tirzepatide work after menopause?

They are on the NIDDK's June 2024 list of six FDA-approved drugs for long-term weight management: orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide (Wegovy) and tirzepatide (Zepbound). It says a doctor may prescribe one for adults with a BMI of 30 or more, or 27 or more with a weight-related problem such as high blood pressure or type 2 diabetes.

On average, the NIDDK says, adults who take prescription weight-management medicines as part of a lifestyle program lose 3% to 12% more of their starting weight after a year than people in a lifestyle program without medicine, and with some medicines more than half of participants lose 10% or more. It's equally clear that the medicines "don't replace physical activity and healthy eating habits."

Here is one study in postmenopausal women specifically, and it is small. A retrospective study from the Mayo Clinic, published in Menopause in 2024, looked at 106 postmenopausal women treated with semaglutide. The 16 who were also on hormone therapy lost more weight at 12 months than the 90 who weren't, 16% versus 12%, and the gap held after adjusting for other factors. The authors call for larger studies to confirm it.

Read that study carefully. In my reading, it's an interesting signal, not a reason to start hormones for weight loss. It was a look back at records, not a trial, and only 16 women were on hormone therapy. A much older Cochrane review of randomized trials found no effect of estrogen, with or without progestogen, on body weight, so the evidence doesn't support hormones as a weight-loss treatment on their own.

Are compounded or online GLP-1 drugs safe?

The FDA has published a list of concerns. It says unapproved versions of GLP-1 drugs, including semaglutide and tirzepatide, don't undergo its review for safety, effectiveness and quality before they're marketed. It says compounded drugs should only be used when a patient's needs can't be met by an FDA-approved drug.

It also advises getting a prescription from your doctor and filling it at a state-licensed pharmacy.

990 and 730+
As of May 31, 2026, the FDA had received 990 reports of adverse events linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. It notes it isn't always possible to tell whether the drug itself caused the event, and that these events are likely underreported, because many compounding pharmacies aren't required to report them. Source: U.S. Food and Drug Administration, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.

The FDA lists warning signs that an online seller may not be legitimate. They include claims that a compounded drug is the same as an approved one, prices that seem too good to be true, medicine that looks different from before or arrives damaged, no screening or prescription by a licensed doctor, and no doctor available for questions afterwards.

  • Multi-dose vials: the FDA recommends discarding a vial within 28 days of first use, even if medicine remains, because the risk of contamination rises.
  • Warm deliveries: it advises not using any injectable GLP-1 that arrives warm or without enough refrigeration.
  • Counterfeits: it is aware of counterfeit Ozempic in the US, which could contain the wrong ingredient, too much, too little or none.
  • Newer names: it says retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any condition.

What happens when you stop a weight-loss medication?

You'll probably regain some weight, the NIDDK says, and building healthy eating habits and more physical activity may help you regain less. It also says that if you don't lose at least 5% of your starting weight after 12 weeks on the full dose, your health care professional will probably advise you to stop and try a different plan.

It says people who have lost enough weight to improve their health, without serious side effects, may be advised to stay on the medicine indefinitely, and that because obesity is a chronic disease, the new eating and activity habits may need to continue for years. In my reading, that's the question to ask at the start, before the first prescription: what's the plan if it works, and what's the plan if it doesn't?

What about berberine, peptides and weight-loss supplements?

Berberine has a small signal, from a review that wasn't about menopause. A 2020 meta-analysis of 12 randomized trials found that berberine reduced body weight by about 2 kg (around 4.5 pounds) on average. Its abstract doesn't describe the trials as studying women in menopause, and 2 kg is modest next to the prescription options above.

Peptides are a different story. The FDA keeps a page on bulk substances used in compounding that may present significant safety risks. Among the peptides it describes are BPC-157 and AOD-9604, whose nominations for compounding were later withdrawn. For both, it says they may pose a risk of immune reactions for certain routes of administration and that it has found no, or only limited, safety information. For AOD-9604, it adds that it has identified serious adverse events that may be associated with it, though causality is not clear.

And the general warnings about supplements apply here too: the FDA doesn't approve them for safety or effectiveness before they're sold. Our guide to menopause supplements covers what the evidence says about the most popular ones, and our blood sugar article covers how blood sugar and sleep interact.

Where to go from here

If you want to understand why the weight came on in the first place, read our menopause weight gain article. If hot flashes are the bigger problem, our hot flashes guide covers the treatments with the strongest evidence. And if sleep is suffering, start with exercise and sleep in menopause.

For how all of this connects to rest and recovery at night, start at the complete perimenopause and menopause sleep guide.

Key takeaways

  • Modest goals count: for people with overweight or obesity, the NIDDK says losing 5% to 10% of your starting weight may lower blood sugar, blood pressure and triglycerides.
  • It may help hot flashes: The Menopause Society recommends weight loss for hot flashes for some women, on limited evidence, possibly more so earlier in the transition.
  • Sustainable eating moved weight a little, for years: in the WHI trial, a lower-fat pattern with no calorie goals led to modest weight loss and no weight gain over 7.5 years.
  • Activity needs may be higher than the minimum: the NIDDK says more than 300 minutes a week may be needed to reach or keep a weight-loss goal, plus strength training.
  • GLP-1 drugs add more, with a doctor: they're approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition, alongside lifestyle changes.
  • Be careful with compounded and online versions: the FDA doesn't review them before sale and lists clear warning signs.

Frequently asked questions

How much weight should I lose during menopause?

For people with overweight or obesity, the NIDDK says losing 5% to 10% of your starting weight may help improve your health by lowering blood sugar, blood pressure and triglycerides. For a 180-pound woman, that is about 9 to 18 pounds. Talk to your doctor about a target that suits your health.

Does losing weight help menopause hot flashes?

It may, for some women. The Menopause Society's 2023 statement recommends weight loss for hot flashes at Levels II to III, meaning the evidence is limited. It says weight loss from behavioral programs has been associated with fewer hot flashes, possibly more so earlier in the menopause transition.

What is the best diet for menopause weight loss?

In the Women's Health Initiative trial of 48,835 postmenopausal women, a lower-fat eating pattern with more vegetables, fruit and grains, and no calorie goals, led to an average 2.2 kg loss in the first year and no weight gain over 7.5 years.

Do semaglutide and tirzepatide work after menopause?

They are FDA-approved for weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related condition, alongside diet and activity. One small retrospective Mayo Clinic study in postmenopausal women linked hormone therapy to more weight loss on semaglutide.

Is compounded semaglutide safe?

The FDA says compounded GLP-1 drugs are not reviewed for safety, effectiveness or quality before they are marketed and should only be used when an FDA-approved drug cannot meet a patient's needs. As of May 31, 2026, it had received 990 adverse event reports linked to compounded semaglutide.

Does berberine help with weight loss in menopause?

A 2020 meta-analysis of 12 randomized trials found berberine reduced body weight by about 2 kg on average, but the review was not about menopause, and its abstract does not describe the trials as studying women in menopause. Berberine is a supplement, so the FDA does not approve it for safety or effectiveness before it is sold.

Sources cited

  1. National Institute of Diabetes and Digestive and Kidney Diseases (NIH). Prescription Medications to Treat Overweight & Obesity. Last reviewed June 2024. www.niddk.nih.gov
  2. The North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. menopause.org (full text, PDF)
  3. Howard BV, Manson JE, Stefanick ML, et al. Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA. 2006;295(1):39-49. PubMed 16391215
  4. Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266-274. PubMed 38446869
  5. Norman RJ, Flight IH, Rees MC. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution. Cochrane Database Syst Rev. 2000;(2):CD001018. PubMed 10796730
  6. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of October 1, 2026. www.fda.gov
  7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. www.fda.gov
  8. Asbaghi O, Ghanbari N, Shekari M, et al. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020;38:43-49. PubMed 32690176
  9. U.S. Food and Drug Administration. FDA 101: Dietary Supplements. www.fda.gov

How this article was checked

The NIDDK page on weight-management medicines, the FDA pages on unapproved GLP-1 drugs and on risky compounding substances, and the full text of The Menopause Society's 2023 nonhormone position statement were read in full. For the studies, the published abstracts were read, and every number is given as the abstract reports it.

Two independent fact-checks found no serious errors; they led to corrections in earlier drafts, mostly to keep populations, dates and safety wording exactly as the sources state them.

It has not been reviewed by a clinician. Ellen Hayes is a researcher and writer, not a doctor, and nothing here is a diagnosis or a substitute for being seen by one.

Illustrated avatar of Ellen Hayes smiling with a mug of tea.

Ellen Hayes

Health & Wellness Writer and Researcher

Hi — I'm Ellen. Weight is the menopause topic with the most noise and the least patience. I wanted one page that says what's been tested, what's only being sold, and how modest the honest numbers are.

I'm not a doctor. I'm not an expert — and I'm never going to talk down to you like one. I'm a woman in the middle of perimenopause who got tired of vague answers, started reading the actual research, and writes it down here in plain English, the way I'd explain it to a friend over coffee. More about Ellen →

Medical disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Weight-loss medicines need a prescription and a doctor's follow-up; never buy them from a seller that doesn't require one, and talk to your doctor before starting a new exercise program or supplement. Read our full medical disclaimer.